Clinical Trial Update: A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])

View source ↗

Summary

This update describes a study of cobimetinib (Cotellic) in adults with BRAF V600 mutation–positive advanced melanoma under the French TAU program. The study has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cotellic (cobimetinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Melanoma | Status: COMPLETED